ViewpointWhat can be achieved with an HIV vaccine?
References (18)
- et al.
Isolation of measles virus from a naturally-immune, asymptomatically re-infected individual
J Clin Virol
(1999) - et al.
Subclinical measles infections in vaccinated seropositive individuals in arctic Greenland
Vaccine
(1989) - et al.
Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa
Lancet
(1999) - et al.
Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children
Lancet
(1991) - et al.
Response to experimental challenge in persons immunized with different rubella vaccines
J Pediatr
(1978) - et al.
Protective immunity against HIV infection: has nature done the experiment for us?
Immunol Today
(1996) - et al.
Immune responses in HIV-exposed seronegatives: have they repelled the virus?
Curr Opin Immunol
(1995) - et al.
The role of nonhuman primates in the development of an AIDS vaccine
AIDS
(1999) - et al.
Estimated susceptibility to asymptomatic secondary immune response against measles in late convalescent and vaccinated persons
J Med Virol
(1998)
Cited by (23)
HIV prevention risks for Black women in Canada
2009, Social Science and MedicineCitation Excerpt :HIV vaccines may be a woman-controlled method, but consequences attached to their use can still create barriers. In addition, HIV vaccines will only be effective if populations are still using existing prevention methods like education, HIV testing and safer sex practices (Levy, 2001). Therefore, preparation for the future requires gathering information to build proactive strategies that will facilitate use of all available HIV prevention.
AIDS vaccine: Efficacy, safety and ethics
2008, VaccineCitation Excerpt :Yet only one AIDS vaccine has reached the Phase III efficacy trial in humans. In the early stage of AIDS vaccine development, scientists had estimated that efficacy of the gp120 vaccine would be between 30 and 50%, or even lower; and subsequent clinical trials did not confirmed these predictions [4]. In this situation, developers of AIDS vaccine shifted from vaccines inducing “sterile immunity” toward a more realistic goal of developing less effective vaccines that could reduce the risk of transmission by decreasing the viral load.
What can HIV vaccine trials teach us about future HIV vaccine dissemination?
2008, VaccineCitation Excerpt :These misconceptions reinforce the importance of ensuring that trial participants understand the necessarily uncertain nature of experimental vaccine efficacy as well as the possibility of receiving a placebo. In terms of the dissemination of future HIV vaccines, evaluation of approaches to providing education around uncertain vaccine efficacy in the context of clinical trials may provide data to support educational interventions to promote behavioral prevention in the likely scenario of deployment of a partially efficacious vaccine [15,23,24]. Similarly, materials that prove effective in educating trial participants about false-positives, vaccine side effects and the impossibility of vaccine-induced HIV infection may build evidence for interventions to support future HIV vaccine dissemination.
HIV risk and prevention in a post-vaccine context
2004, VaccineIs HIV superinfection worrisome?
2003, Lancet